Exact Sciences (EXAS) announced an expanded partnership with Humana (HUM) to enhance access to colorectal cancer screening. Through the partnership, the Cologuard Plus test will be available as an in-network service for eligible Humana Medicare Advantage members nationwide beginning in August. Humana, the fourth largest private insurer in the United States, has approximately 5.8M Medicare Advantage members.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Buy Rating for Exact Sciences Driven by Promising CRC Screening Test and Favorable Market Outlook
- Exact Sciences’ Innovative PCR-Based Blood Test Positions Company for Market Leadership in Colorectal Cancer Screening
- Exact Sciences’ Oncodetect MRD Assay Gains Medicare Coverage, Boosting Long-Term Revenue Potential Amid Competitive Market
- Patent board invalidates Exact Sciences patent for stool samples
- Exact Sciences’ Growth Potential Bolstered by Medicare Coverage and Strategic Investments